免疫功能受损患者新冠疫苗效力:系统综述与荟萃分析
该系统综述与荟萃分析纳入82项前瞻性观察性研究,比较免疫功能受损与免疫正常人群接种新冠疫苗后的血清转化率。结果显示,器官移植受者血清转化率最低,其次为血液肿瘤、免疫介导炎症性疾病和实体瘤患者;HIV感染者与免疫正常者相似。第二剂可提高各患者群血清转化率,但器官移植受者仍较低。第三剂mRNA疫苗对部分无应答者与血清转化相关。
要点
- 器官移植受者接种一剂后血清转化率较免疫正常者低16倍,第二剂后仅约三分之一血清转化。
- 血液肿瘤、免疫介导炎症性疾病和实体瘤患者首剂后血清转化率约减半,第二剂后明显改善。
- HIV感染者血清转化率与免疫正常者相似;第三剂mRNA疫苗对部分无应答者与血清转化相关。
核心结论
- 免疫功能受损患者接种新冠疫苗后血清转化率显著低于免疫正常者,尤其是器官移植受者。
研究设计与样本
- 系统综述与荟萃分析,纳入82项比较免疫功能受损与免疫正常人群接种新冠疫苗效力的前瞻性观察性研究。
主要发现
- 首剂后血液肿瘤患者血清转化风险比为0.40(95%CI 0.32-0.50),免疫介导炎症性疾病为0.53(0.39-0.71),实体瘤为0.55(0.46-0.65),器官移植受者为0.06(0.04-0.09)。
- 第二剂后器官移植受者血清转化风险比为0.39(0.32-0.46),仅约三分之一出现血清转化;血液肿瘤为0.63(0.57-0.69),免疫介导炎症性疾病为0.75(0.69-0.82),实体瘤为0.90(0.88-0.93)。
- HIV感染者与免疫正常对照的血清转化风险比为1.00(0.98-1.01)。
- 11项研究的系统综述显示第三剂mRNA疫苗与实体瘤、血液肿瘤和免疫介导炎症性疾病无应答者的血清转化相关,但移植受者应答不一。
临床怎么用
- 对免疫功能受损患者,尤其是器官移植受者,应预期其接种后血清转化率较低,并考虑针对性干预如第三剂加强针。
局限性
- 纳入研究以mRNA疫苗为主(77项,94%),第三剂应答在移植受者中不一,在HIV感染者和非mRNA疫苗接种者中研究不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of covid-19 vaccines between immunocompromised and immunocompetent people. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, Central Register of Controlled Trials, COVID-19 Open Research Dataset Challenge (CORD-19), and WHO covid-19 databases for studies published between 1 December 2020 and 5 November 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in November 2021 to identify registered but as yet unpublished or ongoing studies. STUDY SELECTION: Prospective observational studies comparing the efficacy of covid-19 vaccination in immunocompromised and immunocompetent participants. METHODS: A frequentist random effects meta-analysis was used to separately pool relative and absolute risks of seroconversion after the first and second doses of a covid-19 vaccine. Systematic review without meta-analysis of SARS-CoV-2 antibody titre levels was performed after first, second, and third vaccine doses and the seroconversion rate after a third dose. Risk of bias and certainty of evidence were assessed. RESULTS: 82 studies were included in the meta-analysis. Of these studies, 77 (94%) used mRNA vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole virus vaccines. 63 studies were assessed to be at low risk of bias and 19 at moderate risk of bias. After one vaccine dose, seroconversion was about half as likely in patients with haematological cancers (risk ratio 0.40, 95% confidence interval 0.32 to 0.50, I2=80%; absolute risk 0.29, 95% confidence interval 0.20 to 0.40, I2=89%), immune mediated inflammatory disorders (0.53, 0.39 to 0.71, I2=89%; 0.29, 0.11 to 0.58, I2=97%), and solid cancers (0.55, 0.46 to 0.65, I2=78%; 0.44, 0.36 to 0.53, I2=84%) compared with immunocompetent controls, whereas organ transplant recipients were 16 times less likely to seroconvert (0.06, 0.04 to 0.09, I2=0%; 0.06, 0.04 to 0.08, I2=0%). After a second dose, seroconversion remained least likely in transplant recipients (0.39, 0.32 to 0.46, I2=92%; 0.35, 0.26 to 0.46), with only a third achieving seroconversion. Seroconversion was increasingly likely in patients with haematological cancers (0.63, 0.57 to 0.69, I2=88%; 0.62, 0.54 to 0.70, I2=90%), immune mediated inflammatory disorders (0.75, 0.69 to 0.82, I2=92%; 0.77, 0.66 to 0.85, I2=93%), and solid cancers (0.90, 0.88 to 0.93, I2=51%; 0.89, 0.86 to 0.91, I2=49%). Seroconversion was similar between people with HIV and immunocompetent controls (1.00, 0.98 to 1.01, I2=0%; 0.97, 0.83 to 1.00, I2=89%). Systematic review of 11 studies showed that a third dose of a covid-19 mRNA vaccine was associated with seroconversion among vaccine non-responders with solid cancers, haematological cancers, and immune mediated inflammatory disorders, although response was variable in transplant recipients and inadequately studied in people with HIV and those receiving non-mRNA vaccines. CONCLUSION: Seroconversion rates after covid-19 vaccination were significantly lower in immunocompromised patients, especially organ transplant recipients. A second dose was associated with consistently improved seroconversion across all patient groups, albeit at a lower magnitude for organ transplant recipients. Targeted interventions for immunocompromised patients, including a third (booster) dose, should be performed. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021272088.
引用
- Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022. PMID: 35236664. doi:10.1136/bmj-2021-068632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。